Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 24 November 2017, 14:07 HKT/SGT

Source: Eisai
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting

TOKYO, Nov 24, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa) and rufinamide (product name: Inovelon, U.S. product name: BANZEL) will be presented at the 71st American Epilepsy Society (AES) Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.

As major presentations, for perampanel this includes a report on the extrapolation of data from Phase III clinical studies on adjunctive treatment to evaluate perampanel for use as monotherapy for partial seizures. Regarding rufinamide, a poster presentation will be given on long-term safety and efficacy of rufinamide for patients with Lennox-Gastaut syndrome (LGS) in a real-world setting in Japan. A total of nine poster presentations will be given at this year's AES meeting.

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. It is available in tablet form to be taken once daily, and a new oral suspension formulation has been approved and is being marketed in the United States. A highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors, it is approved in countries around the world as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, perampanel is approved for use as monotherapy for partial-onset seizures in patients with epilepsy 12 years of age and older in the United States.

Rufinamide is believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in the brain involved in the overexcitement of neurons that potentially causes seizures, so as to prolong their inactive state. The agent is approved as an adjunctive therapy to other AEDs in the treatment of seizures associated with LGS in Europe and the United States. In Japan, the agent is approved as an adjunctive therapy to other AEDs in the treatment of tonic and atonic seizures associated with LGS when therapy with other AEDs is considered inadequate.

Eisai considers neurology a therapeutic area of focus, and strives to maximize the value of perampanel and rufinamide to further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.

Nov 24, 2017 14:07 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Feb 27, 2018 09:33 HKT/SGT
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Feb 21, 2018 08:25 HKT/SGT
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Feb 16, 2018 07:34 HKT/SGT
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Feb 12, 2018 09:03 HKT/SGT
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Feb 1, 2018 16:20 HKT/SGT
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Jan 22, 2018 09:51 HKT/SGT
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Jan 20, 2018 18:32 HKT/SGT
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: